[go: up one dir, main page]

BR0007294A - Formulações farmacêuticas aperfeiçoadas - Google Patents

Formulações farmacêuticas aperfeiçoadas

Info

Publication number
BR0007294A
BR0007294A BR0007294-0A BR0007294A BR0007294A BR 0007294 A BR0007294 A BR 0007294A BR 0007294 A BR0007294 A BR 0007294A BR 0007294 A BR0007294 A BR 0007294A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulations
improved pharmaceutical
perfected
ethanol
mixture
Prior art date
Application number
BR0007294-0A
Other languages
English (en)
Inventor
Laman A Alani
Soumojeet Ghosh
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23269615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0007294(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR0007294A publication Critical patent/BR0007294A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"FORMULAçõES FARMACêUTICAS APERFEIçOADAS". São proporcionadas composições farmacêuticas aperfeiçoadas, compreendendo um ou mais compostos inibidores da protease de HIV tendo propriedades aperfeiçoadas de dissolução em uma mistura de um ácido graxo, etanol, e água.
BR0007294-0A 1999-06-04 2000-05-25 Formulações farmacêuticas aperfeiçoadas BR0007294A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32582699A 1999-06-04 1999-06-04
PCT/US2000/014342 WO2000074677A2 (en) 1999-06-04 2000-05-25 Improved pharmaceutical formulations

Publications (1)

Publication Number Publication Date
BR0007294A true BR0007294A (pt) 2002-08-27

Family

ID=23269615

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0007294-0A BR0007294A (pt) 1999-06-04 2000-05-25 Formulações farmacêuticas aperfeiçoadas

Country Status (32)

Country Link
EP (2) EP1733725B2 (pt)
JP (1) JP4753511B2 (pt)
KR (1) KR100815412B1 (pt)
CN (2) CN100418527C (pt)
AR (2) AR032586A1 (pt)
AT (2) ATE332132T1 (pt)
AU (1) AU778198B2 (pt)
BG (1) BG65445B1 (pt)
BR (1) BR0007294A (pt)
CA (1) CA2371109C (pt)
CL (1) CL2008003491A1 (pt)
CO (1) CO5160323A1 (pt)
CY (2) CY1105237T1 (pt)
CZ (1) CZ301308B6 (pt)
DE (2) DE60029219T2 (pt)
DK (2) DK1733725T4 (pt)
ES (2) ES2265946T3 (pt)
HU (1) HU229501B1 (pt)
IL (3) IL146025A0 (pt)
MX (1) MXPA01012478A (pt)
MY (1) MY127908A (pt)
NO (1) NO328968B1 (pt)
NZ (1) NZ515016A (pt)
PL (1) PL197671B1 (pt)
PT (2) PT1183026E (pt)
SA (1) SA00210237B1 (pt)
SI (2) SI1183026T1 (pt)
SK (2) SK287185B6 (pt)
TR (1) TR200103488T2 (pt)
TW (1) TWI244390B (pt)
WO (1) WO2000074677A2 (pt)
ZA (1) ZA200108641B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
PT1183026E (pt) * 1999-06-04 2006-11-30 Abbott Lab Formulações farmacêuticas melhoradas incluindo ritonavir
US7141593B1 (en) 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
CA2359945C (en) 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
IL150265A0 (en) * 2000-01-19 2002-12-01 Abbott Lab Improved pharmaceutical formulations comprising one or more solubilized hiv protease inhibiting compounds
WO2002096395A1 (en) * 2001-05-25 2002-12-05 Abbott Laboratories Soft elastic capsules comprising ritonavir and/or lopinavir
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
CA2635468C (en) * 2005-12-30 2016-08-09 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
AU2013204805C1 (en) * 2006-07-07 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
NO345893B1 (no) * 2006-07-07 2021-09-27 Gilead Sciences Inc Modulatorer av farmakokinetikkegenskaper til terapeutika
AU2015234299B2 (en) * 2006-07-07 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
AU2015258296B2 (en) * 2006-07-07 2017-08-17 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
ES2796275T3 (es) * 2006-07-07 2020-11-26 Gilead Sciences Inc Moduladores de propiedades farmacocinéticas de agentes terapéuticos
EP2112925A4 (en) 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
AU2013204817B2 (en) * 2007-02-23 2015-05-07 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
SI2487161T2 (sl) 2007-02-23 2024-07-31 Gilead Sciences, Inc. Modulatorji farmakokinetičnih lastnosti terapevtikov
AU2015204378B2 (en) * 2007-02-23 2017-03-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
HUE029842T2 (en) * 2007-02-23 2017-04-28 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
JP5393665B2 (ja) * 2007-07-06 2014-01-22 ギリアード サイエンシーズ， インコーポレイテッド 治療剤の薬物動態特性の調整剤
AU2008346823B2 (en) 2008-01-04 2015-03-12 Gilead Sciences, Inc. Inhibitors of cytochrome P450
UA108738C2 (uk) * 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) † 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
EP0788346B9 (en) * 1994-03-18 2007-02-14 Supernus Pharmaceuticals, Inc. Emulsified drug delivery systems
DE4431489A1 (de) * 1994-09-03 1996-03-07 Heidelberger Baustofftech Gmbh Schnellhärtende aminosilanvernetzende Silikonmassen
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
EP1295874A3 (en) * 1995-12-13 2003-04-02 Abbott Laboratories Retroviral protease inhibiting compounds
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
PT1183026E (pt) * 1999-06-04 2006-11-30 Abbott Lab Formulações farmacêuticas melhoradas incluindo ritonavir

Also Published As

Publication number Publication date
KR20020011994A (ko) 2002-02-09
PL351943A1 (en) 2003-07-14
KR100815412B1 (ko) 2008-03-20
PT1733725E (pt) 2009-06-30
CN1353607A (zh) 2002-06-12
PL197671B1 (pl) 2008-04-30
WO2000074677A2 (en) 2000-12-14
EP1733725A1 (en) 2006-12-20
CY1109135T1 (el) 2014-07-02
NZ515016A (en) 2004-02-27
CN101361723A (zh) 2009-02-11
CA2371109A1 (en) 2000-12-14
CY1105237T1 (el) 2010-03-03
DK1733725T3 (da) 2009-08-03
AU5287700A (en) 2000-12-28
ES2324549T5 (es) 2012-10-31
HU229501B1 (hu) 2014-01-28
EP1183026B1 (en) 2006-07-05
DK1733725T4 (da) 2012-09-17
AR032586A1 (es) 2003-11-19
CA2371109C (en) 2011-04-26
WO2000074677A3 (en) 2001-02-22
ATE429224T1 (de) 2009-05-15
CO5160323A1 (es) 2002-05-30
IL216686A (en) 2014-01-30
DK1183026T3 (da) 2006-11-06
IL216686A0 (en) 2012-01-31
SK17202001A3 (sk) 2002-03-05
EP1183026A2 (en) 2002-03-06
PT1183026E (pt) 2006-11-30
SA00210237B1 (ar) 2006-11-07
CZ20014293A3 (cs) 2002-03-13
AU778198B2 (en) 2004-11-25
BG65445B1 (bg) 2008-08-29
CZ301308B6 (cs) 2010-01-06
HUP0201591A3 (en) 2002-10-28
DE60029219D1 (de) 2006-08-17
TWI244390B (en) 2005-12-01
ES2265946T3 (es) 2007-03-01
SI1733725T1 (sl) 2009-08-31
TR200103488T2 (tr) 2002-04-22
ES2324549T3 (es) 2009-08-10
ATE332132T1 (de) 2006-07-15
JP4753511B2 (ja) 2011-08-24
DE60042092D1 (de) 2009-06-04
EP1733725B1 (en) 2009-04-22
SK287185B6 (sk) 2010-02-08
NO328968B1 (no) 2010-06-28
NO20015670D0 (no) 2001-11-20
BG106239A (en) 2002-08-30
CN100418527C (zh) 2008-09-17
SK286305B6 (en) 2008-07-07
DE60029219T2 (de) 2007-06-28
CL2008003491A1 (es) 2009-03-06
IL146025A0 (en) 2002-07-25
CN101361723B (zh) 2013-11-06
MY127908A (en) 2006-12-29
SI1733725T2 (sl) 2012-10-30
JP2003501386A (ja) 2003-01-14
SI1183026T1 (sl) 2006-10-31
MXPA01012478A (es) 2003-10-14
HUP0201591A2 (en) 2002-09-28
AR064309A2 (es) 2009-03-25
EP1733725B2 (en) 2012-08-08
NO20015670L (no) 2001-11-20
HK1045804A1 (en) 2002-12-13
IL146025A (en) 2012-04-30
ZA200108641B (en) 2003-01-20

Similar Documents

Publication Publication Date Title
BR0007294A (pt) Formulações farmacêuticas aperfeiçoadas
BR0112160A (pt) Agentes antiinflamatórios seletivos para glicocorticóides
BR9908438A (pt) Tabletes de desintegração rápida
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
AU3435497A (en) Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies
ITFI930247A1 (it) Antagonisti delle tachichinine,procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche.
PA8548801A1 (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
BR0109943A (pt) Composições farmacêuticas
CA2303498A1 (en) Dioxocyclopentyl hydroxamic acids
BR9811099A (pt) Inibidores de urocinase
BR9714310A (pt) Composição farmacêutica
ATE370730T1 (de) Pharmazeutische zubereitungen, die chelatbildner/sequestriermittel enthalten und deren dermatologische verwendung
IT1301966B1 (it) Composizioni farmaceutiche ad attivita&#39; analgesica
DE60019334D1 (de) Antivirale arznei
NZ515757A (en) Amorphous compounds and their pharmaceutical compositions
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
BR9809571A (pt) Composição medicinal e processo para produzì-la
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
BR0011864A (pt) Formulações farmacêuticas
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
SE0001916D0 (sv) Novel formulation
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
CO4910113A1 (es) Composiciones farmaceuticas estabilizadas, a base de quinu- pristina y de dalfopristina y su preparacion
ES2086195T3 (es) Nuevos derivados pseudopeptidicos de actividad antagonista de la bradiquinina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DE69828522D1 (de) Antithrombotische mittel

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25B Requested transfer of rights rejected

Owner name: ABBOTT LABORATORIES (US)